Table 1. Patient and disease characteristics at baseline (intention-to-treat population).
| Irinotecan+5- FU/LV | Etoposide+5- FU/LV | |
|---|---|---|
| No. of exposed patients | 56 | 58 |
| Gender (n (%)) | ||
| Male | 40 (71) | 49 (85) |
| Female | 16 (29) | 9 (16) |
| Age (years) | ||
| Median (range) | 61 (41–73) | 63 (34–76) |
| KPS | ||
| Median value | 90 | 85 |
| Distribution (n (%)) | ||
| 60+70 | 3 (5) | 7 (12) |
| 80 | 21 (38) | 22 (38) |
| 90 | 28 (50) | 21 (36) |
| 100 | 4 (7) | 8 (14) |
| Primary tumour location (n (%)) | ||
| Stomach | 37 (66) | 42 (72) |
| Oesophagogastric junction | 19 (34) | 16 (28) |
| Median time (months (range)) since | ||
| Histological confirmation | 1.5 (0–181) | 1.4 (0–65) |
| Diagnosis of metastasis | 0.7 (0–12) | 0.5 (0–13) |
| Prior surgery | ||
| Number with surgery (%) | 29 (52) | 31 (53) |
| Median months since surgery (range) | 7.7 (0–181) | 11.1 (0–65) |
| Location of metastases at entry (n (%)) | ||
| Skin | 0 | 1 (2) |
| Liver | 34 (61) | 37 (64) |
| Lung | 12 (21) | 5 (9) |
| Lymph nodes | 40 (71) | 47 (81) |
| Bone marrow | 0 | 0 |
| Bone | 4 (7) | 1 (2) |
| Peritoneum | 10 (18) | 11 (19) |
| Other | 20 (36) | 23 (40) |
| Number of involved organs (n (%)) | ||
| 1 | 13 (23) | 13 (22) |
| 2 | 25 (45) | 25 (43) |
| 3 | 15 (27) | 18 (31) |
| 4 | 3 (5) | 2 (3) |
KPS=Karnofsky performance score.